May 14 |
Gain Therapeutics GAAP EPS of -$0.22
|
May 14 |
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
|
May 3 |
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
|
Apr 24 |
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
Apr 17 |
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
|
Apr 10 |
Insiders are Piling into These 10 Healthcare Stocks in 2024
|
Apr 10 |
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
|
Apr 9 |
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
|
Apr 8 |
Gain Therapeutics names Gene Mack as CFO
|
Apr 8 |
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
|